India, July 14 -- Shares of Biogen Inc. (BIIB) are falling about 9 percent in Tuesday morning trading despite the company reporting meaningful clinical outcomes and strong biomarker responses in patients with early Alzheimer's disease from its Phase 2 CELIA study of Diranersen.
The company's stock is currently trading at $190.58, down 8.84 percent or $18.47, over the previous close of $209.03 on the Nasdaq. It has traded between $121.05 and $219.72 in the past one year.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....